Revance Therapeutics Inc. (RVNC)

15.07
1.10 7.50
NASDAQ : Health Technology
Prev Close 14.02
Open 14.12
Day Low/High 13.81 / 14.93
52 Wk Low/High 9.88 / 26.89
Volume 317.86K
Avg Volume 354.70K
Exchange NASDAQ
Shares Outstanding 44.10M
Market Cap 537.17M
EPS -3.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Revance Earns Great Place To Work® Certification For Second Year

Revance Earns Great Place To Work® Certification For Second Year

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced the company is certified as a great workplace by the independent analysts at Great...

Revance To Participate In The 2019 Cantor Global Healthcare Conference

Revance To Participate In The 2019 Cantor Global Healthcare Conference

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the 2019 Cantor Global Healthcare Conference...

Revance To Participate In The Morgan Stanley 17th Annual Global Healthcare Conference

Revance To Participate In The Morgan Stanley 17th Annual Global Healthcare Conference

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Morgan Stanley 17th Annual Global...

Revance To Participate In The Wells Fargo 14th Annual Healthcare Conference

Revance To Participate In The Wells Fargo 14th Annual Healthcare Conference

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Wells Fargo 14th Annual Healthcare...

Revance Reports Second Quarter 2019 Financial Results, Provides Corporate Update

Revance Reports Second Quarter 2019 Financial Results, Provides Corporate Update

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today reported financial results for the quarter ended June 30, 2019 and provided a corporate...

Revance To Release Second Quarter 2019 Financial Results On Monday, August 5, 2019

Revance To Release Second Quarter 2019 Financial Results On Monday, August 5, 2019

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will release second quarter 2019 financial results on Monday,...

Revance Adds Life Sciences Audit Executive Chris Nolet To Board Of Directors

Revance Adds Life Sciences Audit Executive Chris Nolet To Board Of Directors

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing a new category of high-performance neuromodulators for use in treating aesthetic and therapeutic conditions, today announced the appointment of Chris Nolet to the company's...

First Week Of RVNC January 2020 Options Trading

First Week Of RVNC January 2020 Options Trading

Investors in Revance Therapeutics Inc saw new options begin trading this week, for the January 2020 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 214 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Revance Therapeutics Is Now Oversold (RVNC)

Revance Therapeutics Is Now Oversold (RVNC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Revance Adds Iconic Brand Builder Jill Beraud To Board Of Directors

Revance Adds Iconic Brand Builder Jill Beraud To Board Of Directors

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing a new category of high-performance neuromodulators for use in treating aesthetic and therapeutic conditions, today announced the appointment of Jill Beraud to the company's...

Revance To Participate In The Goldman Sachs 40th Annual Global Healthcare Conference

Revance To Participate In The Goldman Sachs 40th Annual Global Healthcare Conference

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company will participate in the Goldman Sachs 40th Annual...

Revance To Participate In The RBC Capital Markets 2019 Healthcare Conference

Revance To Participate In The RBC Capital Markets 2019 Healthcare Conference

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company will participate in the RBC Capital Markets 2019...

Revance Therapeutics Becomes Oversold (RVNC)

Revance Therapeutics Becomes Oversold (RVNC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Revance Reports First Quarter 2019 Financial Results And Provides Corporate Update

Revance Reports First Quarter 2019 Financial Results And Provides Corporate Update

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today reported financial results for the quarter ended March 31, 2019 and provided a...

Revance To Release First Quarter 2019 Financial Results On Wednesday, May 8, 2019

Revance To Release First Quarter 2019 Financial Results On Wednesday, May 8, 2019

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company will release first quarter 2018 financial results on...

Oversold Conditions For Revance Therapeutics (RVNC)

Oversold Conditions For Revance Therapeutics (RVNC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Revance Appoints Former Allergan Marketing Veteran Taryn Conway As Vice President Of Marketing

Revance Appoints Former Allergan Marketing Veteran Taryn Conway As Vice President Of Marketing

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced a pivotal addition to its leadership team with the appointment of Taryn...

SAKURA 3 Trial Results Presented On Podium At World's Largest Medical Aesthetic Conference

SAKURA 3 Trial Results Presented On Podium At World's Largest Medical Aesthetic Conference

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced podium and poster presentations of its SAKURA 3 Phase 3 open-label,...

Revance To Participate In The Needham Healthcare Conference

Revance To Participate In The Needham Healthcare Conference

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the Needham Healthcare Conference...

Revance To Participate In Upcoming Investor Conferences

Revance To Participate In Upcoming Investor Conferences

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in two upcoming investor conferences.

Revance Releases Fourth Quarter And Full Year 2018 Results

Revance Releases Fourth Quarter And Full Year 2018 Results

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced results for the fourth quarter and full year ended December 31, 2018...

Revance To Release Fourth Quarter And Full Year 2018 Financial Results On Tuesday, February 26, 2019

Revance To Release Fourth Quarter And Full Year 2018 Financial Results On Tuesday, February 26, 2019

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will release fourth quarter and full year 2018...

Revance Therapeutics Becomes Oversold (RVNC)

Revance Therapeutics Becomes Oversold (RVNC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Revance Announces Closing Of Public Offering Of Common Stock

Revance Announces Closing Of Public Offering Of Common Stock

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions ("Revance" or the "Company"), today announced the closing of an underwritten public...

Revance Announces Pricing Of Public Offering Of Common Stock

Revance Announces Pricing Of Public Offering Of Common Stock

Revance Therapeutics, Inc. (Nasdaq:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions ("Revance" or the "Company"), today announced the pricing of an underwritten public...

Revance Announces Proposed Public Offering Of Common Stock

Revance Announces Proposed Public Offering Of Common Stock

Revance Therapeutics, Inc. (Nasdaq:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions ("Revance" or the "Company"), today announced a proposed underwritten public offering in...

Revance Announces Ground-Breaking Data Presentations At Leading International Neurotoxin Conference

Revance Announces Ground-Breaking Data Presentations At Leading International Neurotoxin Conference

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced 11 clinical and non-clinical presentations for DaxibotulinumtoxinA for...

Revance Highlights Recent Regulatory Progress And Provides Anticipated 2019 Milestones

Revance Highlights Recent Regulatory Progress And Provides Anticipated 2019 Milestones

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced updates on meetings with the U.

TheStreet Quant Rating: D (Sell)